A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

BACKGROUND: While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at earlier stages remain unclear. We compared the cardioprotective effects of empa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cardiovasc Diabetol
Asıl Yazarlar: Hiruma, Shigenori, Shigiyama, Fumika, Hisatake, Shinji, Mizumura, Sunao, Shiraga, Nobuyuki, Hori, Masaaki, Ikeda, Takanori, Hirose, Takahisa, Kumashiro, Naoki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7852076/
https://ncbi.nlm.nih.gov/pubmed/33530982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01228-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller